Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Tipranavir/Ritonavir on Fluconazole PK in Healthy Volunteers
NCT02195466Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2003
- Primary completion
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Area under plasma concentration time curve from 0-24 hours for Fluconazole, Maximum plasma concentration for Fluconazole at 24 hours and 1 more. Started Jun 2003; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02195466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195466.